What is EvolveImmune Therapeutics?
EvolveImmune Therapeutics is at the forefront of developing a unique pipeline of trispecific T cell engagers that incorporate integrated CD2 costimulation. This innovative approach aims to overcome the resistance challenges posed by current immunotherapies in treating cancer. The company's lead drug candidate, EVOLVE104, is slated for clinical trials in 2025, signaling a significant step towards clinical validation. EvolveImmune is dedicated to enhancing the lives of cancer patients through advanced therapeutic solutions, further bolstered by a strategic partnership with Abbvie to explore additional therapeutics leveraging costimulation technology.
How much funding has EvolveImmune Therapeutics raised?
EvolveImmune Therapeutics has raised a total of $37M across 1 funding round:
Other Financing Round
$37M
Other Financing Round (2023): $37M with participation from Bristol-Myers Squibb and Pfizer
Key Investors in EvolveImmune Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering, developing, and manufacturing prescription medications for serious patient needs across oncology, cardiovascular disease, immunoscience, and virology. They invest heavily in R&D and external collaborations to accelerate therapeutic advances.
Pfizer
Pfizer is a biopharmaceutical company engaged in the research, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas, including oncology, internal medicine, and inflammation and immunology.
What's next for EvolveImmune Therapeutics?
The substantial enterprise-level funding EvolveImmune Therapeutics has garnered positions it for accelerated growth and clinical development. This strategic backing is expected to fuel the advancement of its lead candidate, EVOLVE104, through its upcoming clinical trials. The company's focus on overcoming cancer cell resistance through novel trispecific T cell engagers, combined with its partnership with Abbvie, suggests a robust strategy for expanding its therapeutic offerings and market presence. Future investment will likely concentrate on scaling manufacturing, expanding clinical research, and further R&D into its costimulation-based platform.
See full EvolveImmune Therapeutics company page
